Arina Martynchyk, Cameron Wellard, Eliza Chung, Simran K Bhopal, Zoe K McQuilten, Stephen P Mulligan, Stephen Opat, Erica M Wood, Eliza A Hawkes, Mary A Anderson
{"title":"Characteristics of Australian and New Zealand patients with chronic lymphocytic leukaemia: a lymphoma and related diseases registry report.","authors":"Arina Martynchyk, Cameron Wellard, Eliza Chung, Simran K Bhopal, Zoe K McQuilten, Stephen P Mulligan, Stephen Opat, Erica M Wood, Eliza A Hawkes, Mary A Anderson","doi":"10.1111/imj.70037","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Treatment of chronic lymphocytic leukaemia (CLL) has evolved significantly with the advent of targeted agents. Real-world analysis of patients with CLL provides a better understanding of treatment efficacy and toxicity and informs planning of future trials; however, Australasian studies are limited.</p><p><strong>Aims: </strong>Here we describe the demographics, disease characteristics, treatment and outcome for CLL patients enrolled in the Australia and New Zealand Lymphoma and Related Diseases Registry (LaRDR).</p><p><strong>Methods: </strong>This study included 365 patients aged ≥18 years with CLL diagnosed between January 2016 and May 2023.</p><p><strong>Results: </strong>Median age at diagnosis was 68 years, with 65% being male. Median follow-up was 15.2 months (range 0-78). 11q, 13q, 17p deletions and trisomy 12 were detected in 12%, 54%, 11% and 14% respectively. During the period of follow-up, 38% of patients commenced first-line therapy. The use of Bruton's Tyrosine Kinase inhibitors and B-cell lymphoma 2 inhibitors increased more than 10-fold following regulatory approval in 2020. Two-year progression-free and overall survival, measured from commencement of first-line therapy, were 67% (95% CI 55-76) and 87% (95% CI 78-93) respectively.</p><p><strong>Conclusion: </strong>The increasing use of targeted agents largely reflected availability; however, continuing use of chemoimmunotherapy following regulatory approval of targeted agents was noted in 29% of patients in 2022.</p>","PeriodicalId":13625,"journal":{"name":"Internal Medicine Journal","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Internal Medicine Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/imj.70037","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Treatment of chronic lymphocytic leukaemia (CLL) has evolved significantly with the advent of targeted agents. Real-world analysis of patients with CLL provides a better understanding of treatment efficacy and toxicity and informs planning of future trials; however, Australasian studies are limited.
Aims: Here we describe the demographics, disease characteristics, treatment and outcome for CLL patients enrolled in the Australia and New Zealand Lymphoma and Related Diseases Registry (LaRDR).
Methods: This study included 365 patients aged ≥18 years with CLL diagnosed between January 2016 and May 2023.
Results: Median age at diagnosis was 68 years, with 65% being male. Median follow-up was 15.2 months (range 0-78). 11q, 13q, 17p deletions and trisomy 12 were detected in 12%, 54%, 11% and 14% respectively. During the period of follow-up, 38% of patients commenced first-line therapy. The use of Bruton's Tyrosine Kinase inhibitors and B-cell lymphoma 2 inhibitors increased more than 10-fold following regulatory approval in 2020. Two-year progression-free and overall survival, measured from commencement of first-line therapy, were 67% (95% CI 55-76) and 87% (95% CI 78-93) respectively.
Conclusion: The increasing use of targeted agents largely reflected availability; however, continuing use of chemoimmunotherapy following regulatory approval of targeted agents was noted in 29% of patients in 2022.
期刊介绍:
The Internal Medicine Journal is the official journal of the Adult Medicine Division of The Royal Australasian College of Physicians (RACP). Its purpose is to publish high-quality internationally competitive peer-reviewed original medical research, both laboratory and clinical, relating to the study and research of human disease. Papers will be considered from all areas of medical practice and science. The Journal also has a major role in continuing medical education and publishes review articles relevant to physician education.